Physician profile
James K Oneill
NPI 1770878670
$10,963.51
in general payments reported to CMS, 2019-2025
41 companies · $3,517 in 2025
The $3,517 reported for 2025 was more than what 78% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $913 · 2020: $444 · 2021: $238 · 2022: $984 · 2023: $2,173 · 2024: $2,694 · 2025: $3,517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,383.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,119.00 | 2019-2025 | Watchman, Avvigo Guidance System, Comet |
| Abbott Laboratories | $1,087.99 | 2020-2025 | Mitraclip, Aveir, Triclip |
| Amgen INC. | $1,046.52 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $803.57 | 2019-2024 | Xarelto |
| Medtronic, INC. | $756.39 | 2022-2025 | Onyx Frontier, Corevalve Evolut R, Symplicity G3 |
| Abiomed | $731.15 | 2019-2024 | Impella |
| Shockwave Medical, INC | $707.26 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novartis Pharmaceuticals Corporation | $594.41 | 2019-2025 | |
| Edwards Lifesciences Corporation | $517.15 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $451.38 | 2022-2025 | Verquvo, Winrevair, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $384.10 | 2019-2025 | Sotyktu, Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $383.55 | 2019-2025 | Jardiance |
| Irhythm Technologies, INC. | $315.26 | 2023-2024 | Zio Xt Patch, Zio Monitor, Zio At Patch |
| Astrazeneca Pharmaceuticals LP | $299.85 | 2019-2025 | Farxiga, Wainua |
| Bayer Healthcare Pharmaceuticals INC. | $213.80 | 2025 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $160.94 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $156.88 | 2024 | Inpefa |
| Sanofi-Aventis U.S. LLC | $154.48 | 2019-2023 | |
| Cardiovascular Systems INC. | $135.31 | 2022 | |
| Novo Nordisk INC | $126.15 | 2023-2025 | Ozempic, Wegovy |
| Scpharmaceuticals INC. | $102.52 | 2024-2025 | |
| Pfizer INC. | $94.67 | 2019-2025 | |
| Azurity Pharmaceuticals, INC. | $59.12 | 2024 | Edarbi |
| Amarin Pharma, INC. | $54.07 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $52.80 | 2019 | |
| Esperion Therapeutics, INC. | $45.08 | 2021-2025 | Nexletol |
| Arbor Pharmaceuticals, INC. | $44.32 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $39.49 | 2019-2024 | Lifevest |
| Tactile Systems Technology INC | $36.14 | 2023-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Altathera Pharmaceuticals LLC | $35.06 | 2023 | Sotalol Hydrochloride |
| Bridgebio Pharma, INC. | $32.65 | 2025 | Attruby |
| Inspire Medical Systems, INC. | $31.92 | 2025 | Inspire |
| Cardiva Medical, INC. | $26.80 | 2025 | Savvywire |
| W. L. Gore & Associates, INC. | $24.74 | 2025 | Gore Cardioform Septal Occluder |
| Astellas Pharma US INC | $23.47 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $22.50 | 2025 | Uptravi, Opsynvi |
| Cvrx, INC. | $21.60 | 2023 | Barostim Neo System |
| Glaxosmithkline, LLC. | $21.04 | 2025 | Arexvy, Shingrix |
| Agepha Pharma Fz LLC | $17.36 | 2024 | Lodoco |
| Chiesi USA, INC. | $16.59 | 2025 | Kengreal |
| Medtronic Vascular, INC. | $16.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Oneill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.